N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study
- PMID: 20170790
- DOI: 10.1016/j.jacc.2009.08.078
N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study
Abstract
Objectives: This study was designed to investigate whether the addition of N-terminal pro-B-type natriuretic peptide-guided, intensive patient management (BM) to multidisciplinary care (MC) improves outcome in patients following hospitalization due to heart failure (HF).
Background: Patients hospitalized due to HF experience frequent rehospitalizations and high mortality.
Methods: Patients hospitalized due to HF were randomized to BM, MC, or usual care (UC). Multidisciplinary care included 2 consultations from an HF specialist who provided therapeutic recommendations and home care by a specialized HF nurse. In addition, BM included intensified up-titration of medication by HF specialists in high-risk patients. NT-proBNP was used to define the level of risk and to monitor wall stress. This monitoring allowed for anticipation of cardiac decompensation and adjustment of medication in advance.
Results: A total of 278 patients were randomized in 8 Viennese hospitals. After 12 months, the BM group had the highest proportion of antineurohormonal triple-therapy (difference among all groups). Accordingly, BM reduced days of HF hospitalization (488 days) compared with the hospitalization for the MC (1,254 days) and UC (1,588 days) groups (p < 0.0001; significant differences among all groups). Using Kaplan-Meier analysis, the first HF rehospitalization (28%) was lower in the BM versus MC groups (40%; p = 0.06) and the MC versus UC groups (61%; p = 0.01). Moreover, the combined end point of death or HF rehospitalization was lower in the BM (37%) than in the MC group (50%; p < 0.05) and in the MC than in the UC group (65%; p = 0.04). Death rate was similar between the BM (22%) and MC groups (22%), but was lower compared with the UC group (39%; vs. BM: p < 0.02; vs. MC: p < 0.02).
Conclusions: Compared with MC alone, additional BM improves clinical outcome in patients after HF hospitalization. (BNP Guided Care in Addition to Multidisciplinary Care; NCT00355017).
Comment in
-
Therapeutics. Adding NT-proBNP-guided management to multidisciplinary care reduced heart failure rehospitalization days.Ann Intern Med. 2010 Jul 20;153(2):JC1-8. doi: 10.7326/0003-4819-153-2-201007200-02008. Ann Intern Med. 2010. PMID: 20643986 No abstract available.
Similar articles
-
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.J Am Coll Cardiol. 2009 Dec 29;55(1):53-60. doi: 10.1016/j.jacc.2009.02.095. J Am Coll Cardiol. 2009. PMID: 20117364 Clinical Trial.
-
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18. Circ Heart Fail. 2014. PMID: 24352403 Clinical Trial.
-
Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.Am Heart J. 2010 Apr;159(4):532-538.e1. doi: 10.1016/j.ahj.2010.01.005. Am Heart J. 2010. PMID: 20362709 Clinical Trial.
-
Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement.Am J Cardiol. 2008 Feb 4;101(3A):72-5. doi: 10.1016/j.amjcard.2007.11.027. Am J Cardiol. 2008. PMID: 18243863 Review.
-
Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.JACC Heart Fail. 2014 Apr;2(2):148-58. doi: 10.1016/j.jchf.2013.11.007. JACC Heart Fail. 2014. PMID: 24720923 Review.
Cited by
-
What is the optimal place for heart failure treatment and care: home or hospital?Curr Heart Fail Rep. 2013 Sep;10(3):227-31. doi: 10.1007/s11897-013-0144-x. Curr Heart Fail Rep. 2013. PMID: 23797345 Review.
-
Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction.Acta Cardiol Sin. 2023 Mar;39(2):297-308. doi: 10.6515/ACS.202303_39(2).20220926A. Acta Cardiol Sin. 2023. PMID: 36911550 Free PMC article.
-
Biomarkers in the management of heart failure.Curr Treat Options Cardiovasc Med. 2010 Dec;12(6):519-31. doi: 10.1007/s11936-010-0096-3. Curr Treat Options Cardiovasc Med. 2010. PMID: 21063930
-
Death is associated to the type of drug-eluting stent in patients with left ventricular dysfunction and elevated natriuretic peptide levels.Sci Rep. 2021 Jan 28;11(1):2443. doi: 10.1038/s41598-021-81569-x. Sci Rep. 2021. PMID: 33510196 Free PMC article.
-
A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods.Heart Fail Rev. 2014 Aug;19(4):413-9. doi: 10.1007/s10741-014-9440-0. Heart Fail Rev. 2014. PMID: 24953975
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous